TRAIL-R2 (DR5) Monoclonal Antibody (DR5-01-1), FITC | Invitrogen MA1-19759 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

TRAIL-R2 (DR5) Monoclonal Antibody (DR5-01-1), FITC

catalog :

MA1-19759

quantity :

100 ug

price :

US 440.00

clonality :

monoclonal

host :

mouse

conjugate :

FITC

clone name :

DR5-01-1

The same clone is also sold as:

Abcam: ab55863, ab53319, ab166650
Exbio: 11-461-C025, 1F-461-C025, 1F-461-C100, 1P-461-C100, 11-461-C100, 1A-461-C100, 1P-461-C025
OriGene: AM03099PU-N, AM03099RP-N, AM03099FC-N

reactivity :

human

application :

flow cytometry

citations: 1

Reference
Lee S, Moon H, Lee Y, Kang C, Kim S. Potentiation of TRAIL‑induced cell death by nonsteroidal anti‑inflammatory drug in human hepatocellular carcinoma cells through the ER stress‑dependent autophagy pathway. Oncol Rep. 2020;44:1136-1148 pubmed publisher

product information

Product Type :

Antibody

Product Name :

TRAIL-R2 (DR5) Monoclonal Antibody (DR5-01-1), FITC

Catalog # :

MA1-19759

Quantity :

100 ug

Price :

US 440.00

Clonality :

Monoclonal

Purity :

Size-exclusion chromatography

Host :

Mouse

Reactivity :

Human

Applications :

Flow Cytometry: 1-5 ug/mL

Species :

Human

Clone :

DR5-01-1

Isotype :

IgG1

Storage :

4 C, store in dark, DO NOT FREEZE!

Description :

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

Immunogen :

Recombinant fusion protein of human IgG heavy chain and extracellular domain of DR5.

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: 1-5 ug/mL

Aliases :

apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9